Co Development Opportunities Peptone platform targets intrinsically disordered proteins that AlphaFold 3 cannot model, creating a unique modality discovery proposition. This specialized capability is well aligned with pharma programs seeking novel targets, offering potential co development, licensing, or sponsored research collaborations to accelerate drug discovery.

Growth and Leadership Recent leadership hires indicate organizational scale up and readiness for larger multi year partnerships. Engage with Peptone on milestone based collaborations, joint development programs, or CRO style discovery services to complement their AI and physics driven engine.

Regional Partnership Advantage London based with a history of seed and Series A funding and involvement from notable venture investors creates a favorable environment for regional partnerships, academic collaborations, and government funding programs. Target EU UK biotech clusters and explore grant aligned programs or regional co funding to validate and scale their platform.

Tech Enablement Needs Their tech forward approach implies a need for advanced computational chemistry, data infrastructure, and scalable compute. Opportunities exist to offer cloud compute credits, ML tooling, or data management services, as well as specialized CRO services for screening and assay development to accelerate discovery programs.

Niche Market Position IDP targeting as a market niche offers defensible positioning. Proactively reach biotech and pharma pipelines in diseases where disordered proteins play a role, proposing licensing or exclusive discovery rights, joint ventures, or sponsored discovery deals to de-risk early programs.